Dr. Stirling Bryan announced as BC AHSN President as of January 2020

December 6, 2019

Vancouver, Canada (December 6th, 2019) – The board of directors of the British Columbia Academic Health Science Network (BC AHSN) is pleased to announce that Dr. Stirling Bryan has been named the President of the organization as of January 1st, 2020. He replaces Dr. Tom Noseworthy as the organization’s leader; Dr. Noseworthy’s term of office … Continue reading Dr. Stirling Bryan announced as BC AHSN President as of January 2020

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

Xenon Pharmaceuticals Inc.

Xenon’s Epilepsy Programs Continue to Advance Including Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy and Plans for Anticipated Pediatric XEN496 Pivotal Phase 3 Clinical Trial in KCNQ2-DEE Patients Promising New Pre-Clinical Data Support Precision Medicine Approach to Treat Dravet Syndrome with Highly Selective Potentiators of Nav1.1 Xenon Extends Invitation to View its … Continue reading Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

Neoleukin Therapeutics Announces Scientific Advisory Board

December 5, 2019
Neoleukin Therapeutics, Inc.

Preeminent leaders in protein design, structural biology and immunology SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the formation of a Scientific Advisory Board comprised of leaders in the fields of de novo protein design, structural biology and immunology. “This distinguished group of scientific leaders will … Continue reading Neoleukin Therapeutics Announces Scientific Advisory Board

Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

Aurinia Pharmaceuticals

Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care – – Statistically significant results demonstrated in all pre-specified hierarchical secondary endpoints – – Aurinia plans to file an NDA submission to the FDA during the first half of 2020 – – Company to host conference call … Continue reading Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

December 3, 2019
XENON PHARMACEUTICALS INC.

BURNABY, British Columbia, Dec. 03, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, December 4, 2019 at 3:00 pm Eastern Time. A live audio webcast … Continue reading Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019

DelMar Pharmaceuticals Inc.

SAN DIEGO, Dec. 3, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that Mr. Saiid Zarrabian, Chief Executive Officer of DelMar, will be a featured presenter at the LD Micro Invitational Conference on December 10, 2019 at 2:40 pm … Continue reading DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

December 2, 2019
XENON PHARMACEUTICALS INC.

Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All Licensed Products, as well as Option to Co-Fund XEN901 SAN DIEGO and BURNABY, British … Continue reading Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences

XENON PHARMACEUTICALS INC.

BURNABY, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at 8:30 am Eastern Time (5:30 am Pacific Time) today to provide a corporate update on the license and collaboration agreement that was announced this morning … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences

Neoleukin Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

November 26, 2019
Neoleukin Therapeutics, Inc.

SEATTLE, Nov. 26, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Piper Jaffray 31ST Annual Healthcare Conference on Thursday, December 5, 2019 at 2:50 p.m. EST in New York. A live webcast of the presentation will be available from the investors section of … Continue reading Neoleukin Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM

November 25, 2019
DelMar Pharmaceuticals Inc.

Newly-Diagnosed Patients Showing Promising Progression-Free Survival Compared to TMZ Historical Data Recurrent Patients Showing Promising Overall Survival Compared to Lomustine Historical Data SAN DIEGO, Nov. 25, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced interim data on its … Continue reading DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM